nodes	percent_of_prediction	percent_of_DWPC	metapath
Sibutramine—Vestibular disorder—Riluzole—amyotrophic lateral sclerosis	0.0212	0.0238	CcSEcCtD
Sibutramine—Psychotic depression—Riluzole—amyotrophic lateral sclerosis	0.0203	0.0228	CcSEcCtD
Sibutramine—Iron deficiency anaemia—Riluzole—amyotrophic lateral sclerosis	0.0188	0.021	CcSEcCtD
Sibutramine—Major depression—Riluzole—amyotrophic lateral sclerosis	0.0158	0.0177	CcSEcCtD
Sibutramine—Skin nodule—Riluzole—amyotrophic lateral sclerosis	0.0154	0.0172	CcSEcCtD
Sibutramine—Rheumatoid arthritis—Riluzole—amyotrophic lateral sclerosis	0.0141	0.0158	CcSEcCtD
Sibutramine—Skin mass—Riluzole—amyotrophic lateral sclerosis	0.0137	0.0154	CcSEcCtD
Sibutramine—Facial paralysis—Riluzole—amyotrophic lateral sclerosis	0.0134	0.015	CcSEcCtD
Sibutramine—Circumoral paresthesia—Riluzole—amyotrophic lateral sclerosis	0.0131	0.0147	CcSEcCtD
Sibutramine—Nephritis—Riluzole—amyotrophic lateral sclerosis	0.0125	0.014	CcSEcCtD
Sibutramine—Dental caries—Riluzole—amyotrophic lateral sclerosis	0.0114	0.0128	CcSEcCtD
Sibutramine—Manic psychosis—Riluzole—amyotrophic lateral sclerosis	0.0108	0.0121	CcSEcCtD
Sibutramine—Yawning—Riluzole—amyotrophic lateral sclerosis	0.0106	0.0119	CcSEcCtD
Sibutramine—VIIth nerve paralysis—Riluzole—amyotrophic lateral sclerosis	0.0104	0.0116	CcSEcCtD
Sibutramine—Cheilitis—Riluzole—amyotrophic lateral sclerosis	0.01	0.0112	CcSEcCtD
Sibutramine—Furunculosis—Riluzole—amyotrophic lateral sclerosis	0.01	0.0112	CcSEcCtD
Sibutramine—Personality disorder—Riluzole—amyotrophic lateral sclerosis	0.00985	0.011	CcSEcCtD
Sibutramine—Paraesthesia oral—Riluzole—amyotrophic lateral sclerosis	0.00909	0.0102	CcSEcCtD
Sibutramine—Hernia—Riluzole—amyotrophic lateral sclerosis	0.00909	0.0102	CcSEcCtD
Sibutramine—Cerebral ischaemia—Riluzole—amyotrophic lateral sclerosis	0.00882	0.00989	CcSEcCtD
Sibutramine—Furuncle—Riluzole—amyotrophic lateral sclerosis	0.00869	0.00974	CcSEcCtD
Sibutramine—Peripheral vascular disorder—Riluzole—amyotrophic lateral sclerosis	0.00869	0.00974	CcSEcCtD
Sibutramine—SLC6A3—nerve—amyotrophic lateral sclerosis	0.00845	0.138	CbGeAlD
Sibutramine—Bundle branch block—Riluzole—amyotrophic lateral sclerosis	0.00845	0.00947	CcSEcCtD
Sibutramine—Hostility—Riluzole—amyotrophic lateral sclerosis	0.0077	0.00863	CcSEcCtD
Sibutramine—Osteoporosis—Riluzole—amyotrophic lateral sclerosis	0.0076	0.00852	CcSEcCtD
Sibutramine—Cholecystitis—Riluzole—amyotrophic lateral sclerosis	0.00742	0.00832	CcSEcCtD
Sibutramine—Gastric ulcer—Riluzole—amyotrophic lateral sclerosis	0.00733	0.00822	CcSEcCtD
Sibutramine—Completed suicide—Riluzole—amyotrophic lateral sclerosis	0.00725	0.00813	CcSEcCtD
Sibutramine—Generalised oedema—Riluzole—amyotrophic lateral sclerosis	0.00717	0.00803	CcSEcCtD
Sibutramine—Myoclonus—Riluzole—amyotrophic lateral sclerosis	0.00708	0.00794	CcSEcCtD
Sibutramine—Enlargement abdomen—Riluzole—amyotrophic lateral sclerosis	0.00708	0.00794	CcSEcCtD
Sibutramine—Libido increased—Riluzole—amyotrophic lateral sclerosis	0.00701	0.00785	CcSEcCtD
Sibutramine—SLC6A2—nerve—amyotrophic lateral sclerosis	0.00682	0.111	CbGeAlD
Sibutramine—Psoriasis—Riluzole—amyotrophic lateral sclerosis	0.00678	0.0076	CcSEcCtD
Sibutramine—Myasthenia—Riluzole—amyotrophic lateral sclerosis	0.00678	0.0076	CcSEcCtD
Sibutramine—Tooth disorder—Riluzole—amyotrophic lateral sclerosis	0.00657	0.00737	CcSEcCtD
Sibutramine—Supraventricular tachycardia—Riluzole—amyotrophic lateral sclerosis	0.0065	0.00729	CcSEcCtD
Sibutramine—SLC6A3—hindbrain—amyotrophic lateral sclerosis	0.00633	0.103	CbGeAlD
Sibutramine—Intestinal obstruction—Riluzole—amyotrophic lateral sclerosis	0.00625	0.00701	CcSEcCtD
Sibutramine—Hyperventilation—Riluzole—amyotrophic lateral sclerosis	0.00619	0.00694	CcSEcCtD
Sibutramine—SLC6A4—Synaptic Vesicle Pathway—UNC13A—amyotrophic lateral sclerosis	0.00609	0.131	CbGpPWpGaD
Sibutramine—Delusion—Riluzole—amyotrophic lateral sclerosis	0.00602	0.00675	CcSEcCtD
Sibutramine—Lung disorder—Riluzole—amyotrophic lateral sclerosis	0.00602	0.00675	CcSEcCtD
Sibutramine—Apathy—Riluzole—amyotrophic lateral sclerosis	0.00597	0.00669	CcSEcCtD
Sibutramine—Metrorrhagia—Riluzole—amyotrophic lateral sclerosis	0.00597	0.00669	CcSEcCtD
Sibutramine—Laryngitis—Riluzole—amyotrophic lateral sclerosis	0.00591	0.00663	CcSEcCtD
Sibutramine—Flat affect—Riluzole—amyotrophic lateral sclerosis	0.00591	0.00663	CcSEcCtD
Sibutramine—Mania—Riluzole—amyotrophic lateral sclerosis	0.00586	0.00657	CcSEcCtD
Sibutramine—SLC6A4—hindbrain—amyotrophic lateral sclerosis	0.0058	0.0947	CbGeAlD
Sibutramine—Neuritis—Riluzole—amyotrophic lateral sclerosis	0.00571	0.0064	CcSEcCtD
Sibutramine—Glaucoma—Riluzole—amyotrophic lateral sclerosis	0.00566	0.00634	CcSEcCtD
Sibutramine—Ventricular fibrillation—Riluzole—amyotrophic lateral sclerosis	0.00557	0.00624	CcSEcCtD
Sibutramine—Amblyopia—Riluzole—amyotrophic lateral sclerosis	0.00552	0.00619	CcSEcCtD
Sibutramine—Skin ulcer—Riluzole—amyotrophic lateral sclerosis	0.00547	0.00614	CcSEcCtD
Sibutramine—Abscess—Riluzole—amyotrophic lateral sclerosis	0.00539	0.00604	CcSEcCtD
Sibutramine—Petechiae—Riluzole—amyotrophic lateral sclerosis	0.00518	0.00581	CcSEcCtD
Sibutramine—Gamma-glutamyltransferase increased—Riluzole—amyotrophic lateral sclerosis	0.00518	0.00581	CcSEcCtD
Sibutramine—Apnoea—Riluzole—amyotrophic lateral sclerosis	0.00503	0.00564	CcSEcCtD
Sibutramine—Amenorrhoea—Riluzole—amyotrophic lateral sclerosis	0.00485	0.00544	CcSEcCtD
Sibutramine—Accidental injury—Riluzole—amyotrophic lateral sclerosis	0.00482	0.0054	CcSEcCtD
Sibutramine—Ventricular extrasystoles—Riluzole—amyotrophic lateral sclerosis	0.00472	0.00529	CcSEcCtD
Sibutramine—Bone disorder—Riluzole—amyotrophic lateral sclerosis	0.00472	0.00529	CcSEcCtD
Sibutramine—Arthropathy—Riluzole—amyotrophic lateral sclerosis	0.00469	0.00525	CcSEcCtD
Sibutramine—Cellulitis—Riluzole—amyotrophic lateral sclerosis	0.00469	0.00525	CcSEcCtD
Sibutramine—Thinking abnormal—Riluzole—amyotrophic lateral sclerosis	0.00466	0.00522	CcSEcCtD
Sibutramine—Cough increased—Riluzole—amyotrophic lateral sclerosis	0.00466	0.00522	CcSEcCtD
Sibutramine—Glossitis—Riluzole—amyotrophic lateral sclerosis	0.00462	0.00518	CcSEcCtD
Sibutramine—Gout—Riluzole—amyotrophic lateral sclerosis	0.00456	0.00512	CcSEcCtD
Sibutramine—Leukocytosis—Riluzole—amyotrophic lateral sclerosis	0.00454	0.00508	CcSEcCtD
Sibutramine—Hypercholesterolaemia—Riluzole—amyotrophic lateral sclerosis	0.00451	0.00505	CcSEcCtD
Sibutramine—Cataract—Riluzole—amyotrophic lateral sclerosis	0.00448	0.00502	CcSEcCtD
Sibutramine—Gait disturbance—Riluzole—amyotrophic lateral sclerosis	0.00437	0.00489	CcSEcCtD
Sibutramine—Neck pain—Riluzole—amyotrophic lateral sclerosis	0.00431	0.00484	CcSEcCtD
Sibutramine—Phosphatase alkaline increased—Riluzole—amyotrophic lateral sclerosis	0.00426	0.00478	CcSEcCtD
Sibutramine—Ventricular tachycardia—Riluzole—amyotrophic lateral sclerosis	0.00426	0.00478	CcSEcCtD
Sibutramine—Dermatitis contact—Riluzole—amyotrophic lateral sclerosis	0.00421	0.00472	CcSEcCtD
Sibutramine—Abnormal dreams—Riluzole—amyotrophic lateral sclerosis	0.00421	0.00472	CcSEcCtD
Sibutramine—Urinary incontinence—Riluzole—amyotrophic lateral sclerosis	0.00412	0.00461	CcSEcCtD
Sibutramine—Fluid retention—Riluzole—amyotrophic lateral sclerosis	0.00405	0.00454	CcSEcCtD
Sibutramine—Cramps of lower extremities—Riluzole—amyotrophic lateral sclerosis	0.00392	0.00439	CcSEcCtD
Sibutramine—Neoplasm—Riluzole—amyotrophic lateral sclerosis	0.00385	0.00432	CcSEcCtD
Sibutramine—Ecchymosis—Riluzole—amyotrophic lateral sclerosis	0.00385	0.00432	CcSEcCtD
Sibutramine—Hypertonia—Riluzole—amyotrophic lateral sclerosis	0.00374	0.00419	CcSEcCtD
Sibutramine—Sepsis—Riluzole—amyotrophic lateral sclerosis	0.0037	0.00415	CcSEcCtD
Sibutramine—Mental disability—Riluzole—amyotrophic lateral sclerosis	0.0037	0.00415	CcSEcCtD
Sibutramine—Euphoric mood—Riluzole—amyotrophic lateral sclerosis	0.00366	0.0041	CcSEcCtD
Sibutramine—SLC6A3—brainstem—amyotrophic lateral sclerosis	0.00363	0.0593	CbGeAlD
Sibutramine—Ear pain—Riluzole—amyotrophic lateral sclerosis	0.00363	0.00406	CcSEcCtD
Sibutramine—Lymphadenopathy—Riluzole—amyotrophic lateral sclerosis	0.00363	0.00406	CcSEcCtD
Sibutramine—Phlebitis—Riluzole—amyotrophic lateral sclerosis	0.00359	0.00403	CcSEcCtD
Sibutramine—Blood alkaline phosphatase increased—Riluzole—amyotrophic lateral sclerosis	0.00356	0.00399	CcSEcCtD
Sibutramine—Diabetes mellitus—Riluzole—amyotrophic lateral sclerosis	0.00356	0.00399	CcSEcCtD
Sibutramine—Hepatic function abnormal—Riluzole—amyotrophic lateral sclerosis	0.00354	0.00397	CcSEcCtD
Sibutramine—Photosensitivity—Riluzole—amyotrophic lateral sclerosis	0.00352	0.00395	CcSEcCtD
Sibutramine—Vascular purpura—Riluzole—amyotrophic lateral sclerosis	0.00346	0.00388	CcSEcCtD
Sibutramine—Eczema—Riluzole—amyotrophic lateral sclerosis	0.00344	0.00386	CcSEcCtD
Sibutramine—Cardiac failure congestive—Riluzole—amyotrophic lateral sclerosis	0.00341	0.00382	CcSEcCtD
Sibutramine—Injury—Riluzole—amyotrophic lateral sclerosis	0.00337	0.00377	CcSEcCtD
Sibutramine—Libido decreased—Riluzole—amyotrophic lateral sclerosis	0.00334	0.00374	CcSEcCtD
Sibutramine—SLC6A4—brainstem—amyotrophic lateral sclerosis	0.00332	0.0543	CbGeAlD
Sibutramine—Increased appetite—Riluzole—amyotrophic lateral sclerosis	0.00329	0.00369	CcSEcCtD
Sibutramine—Amnesia—Riluzole—amyotrophic lateral sclerosis	0.00329	0.00369	CcSEcCtD
Sibutramine—Atrial fibrillation—Riluzole—amyotrophic lateral sclerosis	0.00326	0.00366	CcSEcCtD
Sibutramine—Thirst—Riluzole—amyotrophic lateral sclerosis	0.00325	0.00364	CcSEcCtD
Sibutramine—Purpura—Riluzole—amyotrophic lateral sclerosis	0.00321	0.0036	CcSEcCtD
Sibutramine—Anaphylactoid reaction—Riluzole—amyotrophic lateral sclerosis	0.0032	0.00358	CcSEcCtD
Sibutramine—Arthritis—Riluzole—amyotrophic lateral sclerosis	0.00318	0.00357	CcSEcCtD
Sibutramine—Osteoarthritis—Riluzole—amyotrophic lateral sclerosis	0.00309	0.00347	CcSEcCtD
Sibutramine—Gastrointestinal haemorrhage—Riluzole—amyotrophic lateral sclerosis	0.00309	0.00347	CcSEcCtD
Sibutramine—Disturbance in sexual arousal—Riluzole—amyotrophic lateral sclerosis	0.00307	0.00344	CcSEcCtD
Sibutramine—Migraine—Riluzole—amyotrophic lateral sclerosis	0.00305	0.00341	CcSEcCtD
Sibutramine—Affect lability—Riluzole—amyotrophic lateral sclerosis	0.00305	0.00341	CcSEcCtD
Sibutramine—Psychotic disorder—Riluzole—amyotrophic lateral sclerosis	0.00302	0.00339	CcSEcCtD
Sibutramine—Face oedema—Riluzole—amyotrophic lateral sclerosis	0.00299	0.00335	CcSEcCtD
Sibutramine—Cardiac arrest—Riluzole—amyotrophic lateral sclerosis	0.00294	0.0033	CcSEcCtD
Sibutramine—Urinary retention—Riluzole—amyotrophic lateral sclerosis	0.00294	0.0033	CcSEcCtD
Sibutramine—Mood swings—Riluzole—amyotrophic lateral sclerosis	0.00293	0.00329	CcSEcCtD
Sibutramine—SLC6A2—brainstem—amyotrophic lateral sclerosis	0.00293	0.0478	CbGeAlD
Sibutramine—Ataxia—Riluzole—amyotrophic lateral sclerosis	0.00291	0.00326	CcSEcCtD
Sibutramine—Dehydration—Riluzole—amyotrophic lateral sclerosis	0.00288	0.00323	CcSEcCtD
Sibutramine—SLC6A3—Parkinsons Disease Pathway—ATXN2—amyotrophic lateral sclerosis	0.00287	0.0615	CbGpPWpGaD
Sibutramine—Liver function test abnormal—Riluzole—amyotrophic lateral sclerosis	0.00286	0.0032	CcSEcCtD
Sibutramine—Orthostatic hypotension—Riluzole—amyotrophic lateral sclerosis	0.00283	0.00317	CcSEcCtD
Sibutramine—Hypokalaemia—Riluzole—amyotrophic lateral sclerosis	0.00282	0.00316	CcSEcCtD
Sibutramine—Aspartate aminotransferase increased—Riluzole—amyotrophic lateral sclerosis	0.00279	0.00312	CcSEcCtD
Sibutramine—Gastritis—Riluzole—amyotrophic lateral sclerosis	0.00274	0.00307	CcSEcCtD
Sibutramine—Muscular weakness—Riluzole—amyotrophic lateral sclerosis	0.00273	0.00306	CcSEcCtD
Sibutramine—Alanine aminotransferase increased—Riluzole—amyotrophic lateral sclerosis	0.00273	0.00306	CcSEcCtD
Sibutramine—Abdominal distension—Riluzole—amyotrophic lateral sclerosis	0.00269	0.00302	CcSEcCtD
Sibutramine—Dysphagia—Riluzole—amyotrophic lateral sclerosis	0.00267	0.003	CcSEcCtD
Sibutramine—Influenza—Riluzole—amyotrophic lateral sclerosis	0.00267	0.003	CcSEcCtD
Sibutramine—Asthma—Riluzole—amyotrophic lateral sclerosis	0.00267	0.003	CcSEcCtD
Sibutramine—Angina pectoris—Riluzole—amyotrophic lateral sclerosis	0.0026	0.00292	CcSEcCtD
Sibutramine—Bronchitis—Riluzole—amyotrophic lateral sclerosis	0.00257	0.00288	CcSEcCtD
Sibutramine—Dysuria—Riluzole—amyotrophic lateral sclerosis	0.0025	0.0028	CcSEcCtD
Sibutramine—Pollakiuria—Riluzole—amyotrophic lateral sclerosis	0.00247	0.00277	CcSEcCtD
Sibutramine—Erectile dysfunction—Riluzole—amyotrophic lateral sclerosis	0.00246	0.00276	CcSEcCtD
Sibutramine—SLC6A2—Na+/Cl- dependent neurotransmitter transporters—SLC6A1—amyotrophic lateral sclerosis	0.00245	0.0526	CbGpPWpGaD
Sibutramine—Photosensitivity reaction—Riluzole—amyotrophic lateral sclerosis	0.00244	0.00274	CcSEcCtD
Sibutramine—Weight increased—Riluzole—amyotrophic lateral sclerosis	0.00243	0.00273	CcSEcCtD
Sibutramine—Pneumonia—Riluzole—amyotrophic lateral sclerosis	0.0024	0.00269	CcSEcCtD
Sibutramine—Depression—Riluzole—amyotrophic lateral sclerosis	0.00238	0.00266	CcSEcCtD
Sibutramine—Acute coronary syndrome—Riluzole—amyotrophic lateral sclerosis	0.00235	0.00263	CcSEcCtD
Sibutramine—Myocardial infarction—Riluzole—amyotrophic lateral sclerosis	0.00234	0.00262	CcSEcCtD
Sibutramine—Neuropathy peripheral—Riluzole—amyotrophic lateral sclerosis	0.00234	0.00262	CcSEcCtD
Sibutramine—Stomatitis—Riluzole—amyotrophic lateral sclerosis	0.00232	0.00261	CcSEcCtD
Sibutramine—Urinary tract infection—Riluzole—amyotrophic lateral sclerosis	0.00232	0.0026	CcSEcCtD
Sibutramine—Sweating—Riluzole—amyotrophic lateral sclerosis	0.00229	0.00256	CcSEcCtD
Sibutramine—Haematuria—Riluzole—amyotrophic lateral sclerosis	0.00227	0.00255	CcSEcCtD
Sibutramine—SLC6A3—spinal cord—amyotrophic lateral sclerosis	0.00226	0.0368	CbGeAlD
Sibutramine—Epistaxis—Riluzole—amyotrophic lateral sclerosis	0.00225	0.00252	CcSEcCtD
Sibutramine—Sinusitis—Riluzole—amyotrophic lateral sclerosis	0.00224	0.00251	CcSEcCtD
Sibutramine—Bradycardia—Riluzole—amyotrophic lateral sclerosis	0.00218	0.00244	CcSEcCtD
Sibutramine—SLC6A3—Na+/Cl- dependent neurotransmitter transporters—SLC6A1—amyotrophic lateral sclerosis	0.00217	0.0466	CbGpPWpGaD
Sibutramine—Haemoglobin—Riluzole—amyotrophic lateral sclerosis	0.00215	0.00241	CcSEcCtD
Sibutramine—Rhinitis—Riluzole—amyotrophic lateral sclerosis	0.00215	0.00241	CcSEcCtD
Sibutramine—Haemorrhage—Riluzole—amyotrophic lateral sclerosis	0.00214	0.0024	CcSEcCtD
Sibutramine—Hypoaesthesia—Riluzole—amyotrophic lateral sclerosis	0.00213	0.00239	CcSEcCtD
Sibutramine—Pharyngitis—Riluzole—amyotrophic lateral sclerosis	0.00212	0.00238	CcSEcCtD
Sibutramine—Oedema peripheral—Riluzole—amyotrophic lateral sclerosis	0.00211	0.00236	CcSEcCtD
Sibutramine—SLC6A4—spinal cord—amyotrophic lateral sclerosis	0.00207	0.0338	CbGeAlD
Sibutramine—SLC6A2—medulla oblongata—amyotrophic lateral sclerosis	0.00204	0.0333	CbGeAlD
Sibutramine—Eye disorder—Riluzole—amyotrophic lateral sclerosis	0.002	0.00224	CcSEcCtD
Sibutramine—Angiopathy—Riluzole—amyotrophic lateral sclerosis	0.00194	0.00218	CcSEcCtD
Sibutramine—Immune system disorder—Riluzole—amyotrophic lateral sclerosis	0.00193	0.00217	CcSEcCtD
Sibutramine—Chills—Riluzole—amyotrophic lateral sclerosis	0.00192	0.00215	CcSEcCtD
Sibutramine—Arrhythmia—Riluzole—amyotrophic lateral sclerosis	0.00191	0.00214	CcSEcCtD
Sibutramine—SLC6A3—nervous system—amyotrophic lateral sclerosis	0.0019	0.031	CbGeAlD
Sibutramine—Alopecia—Riluzole—amyotrophic lateral sclerosis	0.00189	0.00212	CcSEcCtD
Sibutramine—SLC6A4—Monoamine Transport—SLC6A1—amyotrophic lateral sclerosis	0.00188	0.0403	CbGpPWpGaD
Sibutramine—Malnutrition—Riluzole—amyotrophic lateral sclerosis	0.00186	0.00209	CcSEcCtD
Sibutramine—Flatulence—Riluzole—amyotrophic lateral sclerosis	0.00184	0.00206	CcSEcCtD
Sibutramine—SLC6A3—central nervous system—amyotrophic lateral sclerosis	0.00183	0.0299	CbGeAlD
Sibutramine—Tension—Riluzole—amyotrophic lateral sclerosis	0.00183	0.00205	CcSEcCtD
Sibutramine—Dysgeusia—Riluzole—amyotrophic lateral sclerosis	0.00182	0.00205	CcSEcCtD
Sibutramine—Nervousness—Riluzole—amyotrophic lateral sclerosis	0.00181	0.00203	CcSEcCtD
Sibutramine—Back pain—Riluzole—amyotrophic lateral sclerosis	0.0018	0.00202	CcSEcCtD
Sibutramine—Muscle spasms—Riluzole—amyotrophic lateral sclerosis	0.00179	0.00201	CcSEcCtD
Sibutramine—SLC6A3—cerebellum—amyotrophic lateral sclerosis	0.00179	0.0292	CbGeAlD
Sibutramine—Tremor—Riluzole—amyotrophic lateral sclerosis	0.00175	0.00196	CcSEcCtD
Sibutramine—SLC6A4—nervous system—amyotrophic lateral sclerosis	0.00174	0.0285	CbGeAlD
Sibutramine—Ill-defined disorder—Riluzole—amyotrophic lateral sclerosis	0.00173	0.00194	CcSEcCtD
Sibutramine—Anaemia—Riluzole—amyotrophic lateral sclerosis	0.00172	0.00193	CcSEcCtD
Sibutramine—Agitation—Riluzole—amyotrophic lateral sclerosis	0.00171	0.00192	CcSEcCtD
Sibutramine—SLC6A2—Amine compound SLC transporters—SLC6A1—amyotrophic lateral sclerosis	0.0017	0.0365	CbGpPWpGaD
Sibutramine—Angioedema—Riluzole—amyotrophic lateral sclerosis	0.0017	0.00191	CcSEcCtD
Sibutramine—Malaise—Riluzole—amyotrophic lateral sclerosis	0.00168	0.00188	CcSEcCtD
Sibutramine—SLC6A4—central nervous system—amyotrophic lateral sclerosis	0.00168	0.0274	CbGeAlD
Sibutramine—Vertigo—Riluzole—amyotrophic lateral sclerosis	0.00167	0.00188	CcSEcCtD
Sibutramine—Syncope—Riluzole—amyotrophic lateral sclerosis	0.00167	0.00187	CcSEcCtD
Sibutramine—Leukopenia—Riluzole—amyotrophic lateral sclerosis	0.00167	0.00187	CcSEcCtD
Sibutramine—Palpitations—Riluzole—amyotrophic lateral sclerosis	0.00165	0.00185	CcSEcCtD
Sibutramine—Loss of consciousness—Riluzole—amyotrophic lateral sclerosis	0.00164	0.00184	CcSEcCtD
Sibutramine—Cough—Riluzole—amyotrophic lateral sclerosis	0.00163	0.00182	CcSEcCtD
Sibutramine—SLC6A2—Monoamine Transport—SLC6A1—amyotrophic lateral sclerosis	0.00162	0.0347	CbGpPWpGaD
Sibutramine—Convulsion—Riluzole—amyotrophic lateral sclerosis	0.00161	0.00181	CcSEcCtD
Sibutramine—Hypertension—Riluzole—amyotrophic lateral sclerosis	0.00161	0.0018	CcSEcCtD
Sibutramine—Myalgia—Riluzole—amyotrophic lateral sclerosis	0.00159	0.00178	CcSEcCtD
Sibutramine—Chest pain—Riluzole—amyotrophic lateral sclerosis	0.00159	0.00178	CcSEcCtD
Sibutramine—Arthralgia—Riluzole—amyotrophic lateral sclerosis	0.00159	0.00178	CcSEcCtD
Sibutramine—Anxiety—Riluzole—amyotrophic lateral sclerosis	0.00158	0.00177	CcSEcCtD
Sibutramine—Discomfort—Riluzole—amyotrophic lateral sclerosis	0.00157	0.00176	CcSEcCtD
Sibutramine—Dry mouth—Riluzole—amyotrophic lateral sclerosis	0.00155	0.00174	CcSEcCtD
Sibutramine—SLC6A4—Circadian rythm related genes—SETX—amyotrophic lateral sclerosis	0.00154	0.033	CbGpPWpGaD
Sibutramine—Confusional state—Riluzole—amyotrophic lateral sclerosis	0.00153	0.00172	CcSEcCtD
Sibutramine—SLC6A2—nervous system—amyotrophic lateral sclerosis	0.00153	0.025	CbGeAlD
Sibutramine—Anaphylactic shock—Riluzole—amyotrophic lateral sclerosis	0.00152	0.0017	CcSEcCtD
Sibutramine—Oedema—Riluzole—amyotrophic lateral sclerosis	0.00152	0.0017	CcSEcCtD
Sibutramine—Infection—Riluzole—amyotrophic lateral sclerosis	0.00151	0.00169	CcSEcCtD
Sibutramine—SLC6A3—Amine compound SLC transporters—SLC6A1—amyotrophic lateral sclerosis	0.00151	0.0323	CbGpPWpGaD
Sibutramine—Shock—Riluzole—amyotrophic lateral sclerosis	0.0015	0.00168	CcSEcCtD
Sibutramine—Thrombocytopenia—Riluzole—amyotrophic lateral sclerosis	0.00149	0.00167	CcSEcCtD
Sibutramine—Tachycardia—Riluzole—amyotrophic lateral sclerosis	0.00148	0.00166	CcSEcCtD
Sibutramine—Skin disorder—Riluzole—amyotrophic lateral sclerosis	0.00148	0.00166	CcSEcCtD
Sibutramine—SLC6A2—central nervous system—amyotrophic lateral sclerosis	0.00148	0.0241	CbGeAlD
Sibutramine—Hyperhidrosis—Riluzole—amyotrophic lateral sclerosis	0.00147	0.00165	CcSEcCtD
Sibutramine—SLC6A4—Synaptic Vesicle Pathway—SLC1A3—amyotrophic lateral sclerosis	0.00145	0.0311	CbGpPWpGaD
Sibutramine—SLC6A3—brain—amyotrophic lateral sclerosis	0.00145	0.0237	CbGeAlD
Sibutramine—Anorexia—Riluzole—amyotrophic lateral sclerosis	0.00145	0.00162	CcSEcCtD
Sibutramine—SLC6A3—Monoamine Transport—SLC6A1—amyotrophic lateral sclerosis	0.00143	0.0307	CbGpPWpGaD
Sibutramine—Hypotension—Riluzole—amyotrophic lateral sclerosis	0.00142	0.00159	CcSEcCtD
Sibutramine—Musculoskeletal discomfort—Riluzole—amyotrophic lateral sclerosis	0.00139	0.00155	CcSEcCtD
Sibutramine—Insomnia—Riluzole—amyotrophic lateral sclerosis	0.00138	0.00154	CcSEcCtD
Sibutramine—Paraesthesia—Riluzole—amyotrophic lateral sclerosis	0.00137	0.00153	CcSEcCtD
Sibutramine—Dyspnoea—Riluzole—amyotrophic lateral sclerosis	0.00136	0.00152	CcSEcCtD
Sibutramine—Somnolence—Riluzole—amyotrophic lateral sclerosis	0.00135	0.00152	CcSEcCtD
Sibutramine—Dyspepsia—Riluzole—amyotrophic lateral sclerosis	0.00134	0.0015	CcSEcCtD
Sibutramine—SLC6A4—brain—amyotrophic lateral sclerosis	0.00133	0.0217	CbGeAlD
Sibutramine—Decreased appetite—Riluzole—amyotrophic lateral sclerosis	0.00132	0.00148	CcSEcCtD
Sibutramine—Gastrointestinal disorder—Riluzole—amyotrophic lateral sclerosis	0.00131	0.00147	CcSEcCtD
Sibutramine—Constipation—Riluzole—amyotrophic lateral sclerosis	0.0013	0.00146	CcSEcCtD
Sibutramine—Pain—Riluzole—amyotrophic lateral sclerosis	0.0013	0.00146	CcSEcCtD
Sibutramine—Feeling abnormal—Riluzole—amyotrophic lateral sclerosis	0.00125	0.0014	CcSEcCtD
Sibutramine—Gastrointestinal pain—Riluzole—amyotrophic lateral sclerosis	0.00124	0.00139	CcSEcCtD
Sibutramine—Urticaria—Riluzole—amyotrophic lateral sclerosis	0.00121	0.00135	CcSEcCtD
Sibutramine—Body temperature increased—Riluzole—amyotrophic lateral sclerosis	0.0012	0.00135	CcSEcCtD
Sibutramine—Abdominal pain—Riluzole—amyotrophic lateral sclerosis	0.0012	0.00135	CcSEcCtD
Sibutramine—SLC6A2—brain—amyotrophic lateral sclerosis	0.00117	0.0191	CbGeAlD
Sibutramine—Hypersensitivity—Riluzole—amyotrophic lateral sclerosis	0.00112	0.00126	CcSEcCtD
Sibutramine—Asthenia—Riluzole—amyotrophic lateral sclerosis	0.00109	0.00122	CcSEcCtD
Sibutramine—Pruritus—Riluzole—amyotrophic lateral sclerosis	0.00108	0.00121	CcSEcCtD
Sibutramine—Diarrhoea—Riluzole—amyotrophic lateral sclerosis	0.00104	0.00117	CcSEcCtD
Sibutramine—Dizziness—Riluzole—amyotrophic lateral sclerosis	0.00101	0.00113	CcSEcCtD
Sibutramine—Vomiting—Riluzole—amyotrophic lateral sclerosis	0.000967	0.00108	CcSEcCtD
Sibutramine—Rash—Riluzole—amyotrophic lateral sclerosis	0.000959	0.00107	CcSEcCtD
Sibutramine—Dermatitis—Riluzole—amyotrophic lateral sclerosis	0.000958	0.00107	CcSEcCtD
Sibutramine—Headache—Riluzole—amyotrophic lateral sclerosis	0.000953	0.00107	CcSEcCtD
Sibutramine—SLC6A4—SIDS Susceptibility Pathways—ECE1—amyotrophic lateral sclerosis	0.000922	0.0198	CbGpPWpGaD
Sibutramine—Nausea—Riluzole—amyotrophic lateral sclerosis	0.000903	0.00101	CcSEcCtD
Sibutramine—SLC6A3—Parkinsons Disease Pathway—CASP9—amyotrophic lateral sclerosis	0.00086	0.0184	CbGpPWpGaD
Sibutramine—CYP3A4—nervous system—amyotrophic lateral sclerosis	0.000853	0.0139	CbGeAlD
Sibutramine—CYP3A4—central nervous system—amyotrophic lateral sclerosis	0.000821	0.0134	CbGeAlD
Sibutramine—SLC6A4—NRF2 pathway—GSR—amyotrophic lateral sclerosis	0.000763	0.0163	CbGpPWpGaD
Sibutramine—SLC6A2—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC6A1—amyotrophic lateral sclerosis	0.000666	0.0143	CbGpPWpGaD
Sibutramine—SLC6A2—NRF2 pathway—GSR—amyotrophic lateral sclerosis	0.000656	0.0141	CbGpPWpGaD
Sibutramine—SLC6A4—SIDS Susceptibility Pathways—AQP4—amyotrophic lateral sclerosis	0.000594	0.0127	CbGpPWpGaD
Sibutramine—SLC6A4—SIDS Susceptibility Pathways—SLC1A3—amyotrophic lateral sclerosis	0.000594	0.0127	CbGpPWpGaD
Sibutramine—SLC6A4—SIDS Susceptibility Pathways—CHAT—amyotrophic lateral sclerosis	0.000594	0.0127	CbGpPWpGaD
Sibutramine—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—RARA—amyotrophic lateral sclerosis	0.000593	0.0127	CbGpPWpGaD
Sibutramine—SLC6A3—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC6A1—amyotrophic lateral sclerosis	0.00059	0.0126	CbGpPWpGaD
Sibutramine—SLC6A3—NRF2 pathway—GSR—amyotrophic lateral sclerosis	0.000581	0.0125	CbGpPWpGaD
Sibutramine—SLC6A4—NRF2 pathway—SLC6A1—amyotrophic lateral sclerosis	0.000559	0.012	CbGpPWpGaD
Sibutramine—SLC6A3—Transmission across Chemical Synapses—KCNJ10—amyotrophic lateral sclerosis	0.00049	0.0105	CbGpPWpGaD
Sibutramine—SLC6A2—NRF2 pathway—SLC6A1—amyotrophic lateral sclerosis	0.00048	0.0103	CbGpPWpGaD
Sibutramine—SLC6A3—Transmission across Chemical Synapses—GRIA2—amyotrophic lateral sclerosis	0.000452	0.00968	CbGpPWpGaD
Sibutramine—SLC6A3—Transmission across Chemical Synapses—SLC1A2—amyotrophic lateral sclerosis	0.000436	0.00935	CbGpPWpGaD
Sibutramine—SLC6A4—NRF2 pathway—SQSTM1—amyotrophic lateral sclerosis	0.000431	0.00922	CbGpPWpGaD
Sibutramine—SLC6A3—NRF2 pathway—SLC6A1—amyotrophic lateral sclerosis	0.000425	0.00912	CbGpPWpGaD
Sibutramine—SLC6A4—Circadian rythm related genes—CST3—amyotrophic lateral sclerosis	0.00041	0.00877	CbGpPWpGaD
Sibutramine—SLC6A2—SLC-mediated transmembrane transport—SLC1A2—amyotrophic lateral sclerosis	0.000399	0.00856	CbGpPWpGaD
Sibutramine—SLC6A3—Transmission across Chemical Synapses—NEFL—amyotrophic lateral sclerosis	0.000399	0.00855	CbGpPWpGaD
Sibutramine—SLC6A3—Neuronal System—KCNJ10—amyotrophic lateral sclerosis	0.000375	0.00804	CbGpPWpGaD
Sibutramine—SLC6A3—Transmission across Chemical Synapses—CHAT—amyotrophic lateral sclerosis	0.000371	0.00795	CbGpPWpGaD
Sibutramine—SLC6A3—Transmission across Chemical Synapses—SLC1A3—amyotrophic lateral sclerosis	0.000371	0.00795	CbGpPWpGaD
Sibutramine—SLC6A2—NRF2 pathway—SQSTM1—amyotrophic lateral sclerosis	0.00037	0.00793	CbGpPWpGaD
Sibutramine—SLC6A3—Parkinsons Disease Pathway—CASP3—amyotrophic lateral sclerosis	0.000362	0.00776	CbGpPWpGaD
Sibutramine—SLC6A3—SLC-mediated transmembrane transport—SLC1A2—amyotrophic lateral sclerosis	0.000354	0.00758	CbGpPWpGaD
Sibutramine—SLC6A3—Neuronal System—GRIA2—amyotrophic lateral sclerosis	0.000346	0.00742	CbGpPWpGaD
Sibutramine—SLC6A2—SLC-mediated transmembrane transport—SLC1A3—amyotrophic lateral sclerosis	0.00034	0.00728	CbGpPWpGaD
Sibutramine—SLC6A4—NRF2 pathway—GSTP1—amyotrophic lateral sclerosis	0.000337	0.00722	CbGpPWpGaD
Sibutramine—SLC6A3—Neuronal System—SLC1A2—amyotrophic lateral sclerosis	0.000334	0.00716	CbGpPWpGaD
Sibutramine—SLC6A3—Transmission across Chemical Synapses—SLC6A1—amyotrophic lateral sclerosis	0.000331	0.00709	CbGpPWpGaD
Sibutramine—SLC6A3—NRF2 pathway—SQSTM1—amyotrophic lateral sclerosis	0.000328	0.00703	CbGpPWpGaD
Sibutramine—SLC6A2—Transmembrane transport of small molecules—TRPM7—amyotrophic lateral sclerosis	0.000315	0.00675	CbGpPWpGaD
Sibutramine—SLC6A4—SIDS Susceptibility Pathways—BDNF—amyotrophic lateral sclerosis	0.000307	0.00659	CbGpPWpGaD
Sibutramine—SLC6A3—Neuronal System—NEFL—amyotrophic lateral sclerosis	0.000306	0.00655	CbGpPWpGaD
Sibutramine—SLC6A2—SLC-mediated transmembrane transport—SLC6A1—amyotrophic lateral sclerosis	0.000303	0.00649	CbGpPWpGaD
Sibutramine—SLC6A3—SLC-mediated transmembrane transport—SLC1A3—amyotrophic lateral sclerosis	0.000301	0.00645	CbGpPWpGaD
Sibutramine—SLC6A2—NRF2 pathway—GSTP1—amyotrophic lateral sclerosis	0.00029	0.0062	CbGpPWpGaD
Sibutramine—SLC6A3—Neuronal System—CHAT—amyotrophic lateral sclerosis	0.000284	0.00609	CbGpPWpGaD
Sibutramine—SLC6A3—Neuronal System—SLC1A3—amyotrophic lateral sclerosis	0.000284	0.00609	CbGpPWpGaD
Sibutramine—SLC6A3—Transmembrane transport of small molecules—TRPM7—amyotrophic lateral sclerosis	0.000279	0.00598	CbGpPWpGaD
Sibutramine—SLC6A3—SLC-mediated transmembrane transport—SLC6A1—amyotrophic lateral sclerosis	0.000268	0.00574	CbGpPWpGaD
Sibutramine—SLC6A3—NRF2 pathway—GSTP1—amyotrophic lateral sclerosis	0.000257	0.0055	CbGpPWpGaD
Sibutramine—SLC6A3—Neuronal System—SLC6A1—amyotrophic lateral sclerosis	0.000253	0.00543	CbGpPWpGaD
Sibutramine—SLC6A2—Transmembrane transport of small molecules—SLC1A2—amyotrophic lateral sclerosis	0.000203	0.00435	CbGpPWpGaD
Sibutramine—SLC6A3—Transmembrane transport of small molecules—SLC1A2—amyotrophic lateral sclerosis	0.00018	0.00385	CbGpPWpGaD
Sibutramine—SLC6A2—Transmembrane transport of small molecules—AQP4—amyotrophic lateral sclerosis	0.000173	0.0037	CbGpPWpGaD
Sibutramine—SLC6A2—Transmembrane transport of small molecules—SLC1A3—amyotrophic lateral sclerosis	0.000173	0.0037	CbGpPWpGaD
Sibutramine—CYP3A4—Metapathway biotransformation—GSR—amyotrophic lateral sclerosis	0.000154	0.0033	CbGpPWpGaD
Sibutramine—SLC6A2—Transmembrane transport of small molecules—SLC6A1—amyotrophic lateral sclerosis	0.000154	0.0033	CbGpPWpGaD
Sibutramine—SLC6A4—SIDS Susceptibility Pathways—CASP3—amyotrophic lateral sclerosis	0.000154	0.00329	CbGpPWpGaD
Sibutramine—SLC6A3—Transmembrane transport of small molecules—AQP4—amyotrophic lateral sclerosis	0.000153	0.00328	CbGpPWpGaD
Sibutramine—SLC6A3—Transmembrane transport of small molecules—SLC1A3—amyotrophic lateral sclerosis	0.000153	0.00328	CbGpPWpGaD
Sibutramine—SLC6A3—Transmembrane transport of small molecules—SLC6A1—amyotrophic lateral sclerosis	0.000136	0.00292	CbGpPWpGaD
Sibutramine—SLC6A4—SIDS Susceptibility Pathways—VEGFA—amyotrophic lateral sclerosis	0.00013	0.00279	CbGpPWpGaD
Sibutramine—SLC6A4—Circadian rythm related genes—TP53—amyotrophic lateral sclerosis	8.04e-05	0.00172	CbGpPWpGaD
Sibutramine—CYP3A4—Biological oxidations—GSTP1—amyotrophic lateral sclerosis	6.89e-05	0.00148	CbGpPWpGaD
Sibutramine—CYP3A4—Metapathway biotransformation—GSTP1—amyotrophic lateral sclerosis	6.8e-05	0.00146	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—TPK1—amyotrophic lateral sclerosis	5.28e-05	0.00113	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—VAPB—amyotrophic lateral sclerosis	5.28e-05	0.00113	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—VAPA—amyotrophic lateral sclerosis	4.83e-05	0.00103	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—SACM1L—amyotrophic lateral sclerosis	4.49e-05	0.000962	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—FIG4—amyotrophic lateral sclerosis	4.22e-05	0.000905	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—DAO—amyotrophic lateral sclerosis	3.82e-05	0.000818	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—PLB1—amyotrophic lateral sclerosis	2.89e-05	0.00062	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—GSR—amyotrophic lateral sclerosis	2.67e-05	0.000572	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—CHAT—amyotrophic lateral sclerosis	2.19e-05	0.00047	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—GSTP1—amyotrophic lateral sclerosis	1.18e-05	0.000253	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	1.08e-05	0.000232	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—APOE—amyotrophic lateral sclerosis	8.91e-06	0.000191	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—PTGS2—amyotrophic lateral sclerosis	6.11e-06	0.000131	CbGpPWpGaD
